iANTHUS CAPITAL HOLDINGS (ITHUF) Total Non-Current Liabilities (2020 - 2026)
iANTHUS CAPITAL HOLDINGS's (ITHUF) quarterly Total Non-Current Liabilities came in at $370.0 million in Q1 2026, up 11.47% year-on-year from $332.0 million in Q1 2025, and up 3.74% quarter-over-quarter from $356.7 million in Q4 2025.
iANTHUS CAPITAL HOLDINGS (ITHUF) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
iANTHUS CAPITAL HOLDINGS has disclosed Total Non-Current Liabilities across 7 years of filings, most recently posting $370.0 million for Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $370.0 million, up 11.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $370.0 million (up 11.47% YoY), and the FY2025 annual result was $356.7 million, up 6.97% from the prior year.
- Total Non-Current Liabilities came in at $370.0 million for Q1 2026 at iANTHUS CAPITAL HOLDINGS, up from $356.7 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $392.0 million in Q1 2022 to a low of $292.5 million in Q4 2022.
- The 5-year median for Total Non-Current Liabilities is $339.1 million (2023), against an average of $335.4 million.
- Peak annual rise in Total Non-Current Liabilities reached 16.88% in 2022, while the deepest fall reached 20.65% in 2022.
- iANTHUS CAPITAL HOLDINGS's Total Non-Current Liabilities stood at $292.5 million in 2022, then rose by 15.93% to $339.1 million in 2023, then decreased by 1.66% to $333.5 million in 2024, then advanced by 6.97% to $356.7 million in 2025, then gained by 3.74% to $370.0 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $370.0 million (Q1 2026), $356.7 million (Q4 2025), and $342.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.81 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.13 Bn |
| 10 | iANTHUS CAPITAL HOLDINGS | - | - | 15.92 Mn | 370.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 370.04 Mn |
| Dec 31, 2025 | 356.71 Mn |
| Sep 30, 2025 | 342.87 Mn |
| Jun 30, 2025 | 342.91 Mn |
| Mar 31, 2025 | 331.98 Mn |
| Dec 31, 2024 | 333.46 Mn |
| Dec 31, 2023 | 339.07 Mn |
| Dec 31, 2022 | 292.48 Mn |
| Sep 30, 2022 | 294.39 Mn |
| Jun 30, 2022 | 293.32 Mn |
| Mar 31, 2022 | 391.97 Mn |
| Dec 31, 2021 | 368.61 Mn |
| Sep 30, 2021 | 362.31 Mn |
| Jun 30, 2021 | 347.61 Mn |
| Mar 31, 2021 | 335.37 Mn |
| Dec 31, 2020 | 305.56 Mn |